#None #Innocan Pharma #Intellectual Property #CBD Injection Technology

Innocan Pharma Expands Its CBD Injection Patent Coverage and Announces Private Placement

In a bid to solidify its innovative presence in the pharmaceutical landscape, Innocan Pharma Corporation, a leader in the biotech sector, has announced the expansion of its intellectual property coverage for its liposomal CBD injections throughout Asia. This strategic move is anticipated to maximize the company's growth in one of the world's largest pharmaceutical markets.

Expanding Intellectual Property Across Asia

On April 7, 2025, Innocan revealed that it filed a divisional application for its Chinese patent concerning its liposome-based CBD technology. This follows the grant of a patent in India for a similar prolonged-release formulation, emphasizing Innocan's commitment to protecting its innovations in rapidly growing markets. With a valuation of approximately $163 billion in 2023 for the pharmaceutical industry in China, this step is designed to ensure comprehensive protection and enhance Innocan's competitive advantage in Asia's booming market.

The newly filed application safeguards Innocan's synthetic CBD-loaded Liposome Injection Platform (LPT-CBD), formulated through collaboration with notable scientists from the Hebrew University in Jerusalem. This advanced drug delivery method not only promotes extended exposure but also augments the bioavailability and therapeutic effects of CBD, making it a unique offering in the non-opioid pain management sector.

Innocan's CEO, Iris Bincovich, shared enthusiasm regarding the recent patent application, stating, "Establishing a comprehensive global patent strategy allows us to effectively support the company's broader aspirations in the global pharmaceutical marketplace, especially within the dynamic Asian region." Her insights underscore the management’s forward-looking approach to solidifying Innocan's influence across continents.

Dr. Eyal Kalo, Innocan's Vice President of Research and Development, highlighted the efficacy of LPT-CBD across various animal models dealing with chronic pain, which demonstrates sustained pharmacokinetics. Kalo's commitment to the innovation process illustrates the effectiveness of collaborative approaches in pharmaceutical advancements and the importance of securing robust intellectual property rights for innovative solutions.

Upcoming Private Placement

Innocan also announced plans for a private placement, intending to raise CAD $150,000 through the sale of 833,333 units, priced at CAD $0.18 each. This offering, expected to close shortly on or around April 14, 2025, signifies the company’s dedication to funding its critical operating and corporate strategies.

Each unit sold in this placement will consist of one common share, along with a share purchase warrant, further enhancing the investment's appeal. The warrants will allow holders to purchase additional shares at CAD $0.25 over a span of four years. This move not only demonstrates Innocan’s confidence in its market position but also signals to investors the prospective profitability of the company amid expanding operations.

Innocan plans to allocate the proceeds from this private placement towards ongoing working capital needs and general corporate expenditures, ensuring that the organizational framework supports its ambitious growth plans. Additionally, any securities issued in this placement will be subject to a hold period in accordance with relevant Canadian laws, highlighting the company’s compliance focus within the pharmaceutical market.

Innocan Pharma emerges as an innovator in both pharmaceutical and wellness sectors, notably with its CBD-loaded liposome platform focusing on precise dosing and extended release. Furthermore, Innocan markets a diverse portfolio of high-performance self-care products aimed at enhancing healthier lifestyles through another subsidiary, BI Sky Global Ltd.

As Innocan continues to reinforce its presence in significant pharmaceutical markets and attract strategic investments, the company stands poised for robust growth, with the potential to make substantive impacts on chronic pain management and overall patient care across the globe. The interplay of effective intellectual property strategies and investment opportunities will undoubtedly support Innocan in navigating the competitive landscape of the Asian pharmaceutical market and beyond.